Esperion Therapeutics, Inc. (ESPR) Scheduled to Post Earnings on Wednesday
Esperion Therapeutics, Inc. (NASDAQ:ESPR) is scheduled to release its earnings data before the market opens on Wednesday, November 1st. Analysts expect Esperion Therapeutics to post earnings of ($1.79) per share for the quarter.
Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.25). During the same quarter in the prior year, the business earned ($0.62) earnings per share. On average, analysts expect Esperion Therapeutics to post $-7.12 EPS for the current fiscal year and $-5.96 EPS for the next fiscal year.
Esperion Therapeutics, Inc. (NASDAQ ESPR) opened at 44.05 on Wednesday. The firm’s market cap is $995.22 million. The stock has a 50 day moving average price of $51.17 and a 200 day moving average price of $43.93. Esperion Therapeutics, Inc. has a 52-week low of $9.40 and a 52-week high of $57.40.
A number of research analysts recently weighed in on ESPR shares. UBS AG reiterated a “buy” rating and issued a $57.00 price objective (up from $52.00) on shares of Esperion Therapeutics in a research note on Tuesday, June 27th. Jefferies Group LLC started coverage on shares of Esperion Therapeutics in a research note on Monday, July 10th. They issued a “hold” rating and a $55.00 price objective for the company. BidaskClub lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 4th. Needham & Company LLC lifted their price objective on shares of Esperion Therapeutics from $58.00 to $72.00 and gave the company a “positive” rating in a research note on Tuesday, August 8th. Finally, Deutsche Bank AG set a $64.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 9th. Six research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $58.92.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.